New York State Common Retirement Fund Buys 192,279 Shares of Pfizer Inc. $PFE

New York State Common Retirement Fund grew its position in shares of Pfizer Inc. (NYSE:PFE) by 2.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,681,299 shares of the biopharmaceutical company’s stock after purchasing an additional 192,279 shares during the quarter. New York State Common Retirement Fund’s holdings in Pfizer were worth $210,435,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer during the first quarter worth $27,000. Curio Wealth LLC grew its holdings in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new position in shares of Pfizer in the 1st quarter worth about $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer in the 2nd quarter valued at about $29,000. Finally, Evelyn Partners Asset Management Ltd acquired a new position in shares of Pfizer in the 2nd quarter valued at about $33,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $25.76 on Friday. The company has a market cap of $146.46 billion, a P/E ratio of 13.70, a PEG ratio of 0.81 and a beta of 0.54. The company has a fifty day simple moving average of $25.01 and a 200 day simple moving average of $24.57. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s payout ratio is 100.00%.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Morgan Stanley reduced their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $28.39.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.